RT 001

Drug Profile

RT 001

Alternative Names: Di-deuterated ethyl linoleate; Di-deuterated linoleic acid ethyl ester; RT001

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Retrotope
  • Class Unsaturated fatty acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurodegenerative disorders; Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Friedreich's ataxia
  • Clinical Phase Unknown Brain disorders
  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 09 Nov 2017 Retrotope announces intention to submit NDA to the US FDA for Friedreich’s ataxia in 2018 (Retrotope website, November 2017).
  • 09 Nov 2017 Retrotope has patent protection for fatty acid lipid drugs for the treatment of neurodegenrative and neuromuscular diseases until 2032 (Retrotope website, November 2017).
  • 09 Nov 2017 Retrotope receives patent protection for D-polyunsaturatedvfatty acid (D-PUFA) composition until 2030 (Retrotope website, November 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top